LEADER 01622nam 2200397 450 001 9910583389903321 005 20230120002804.0 010 $a0-323-54950-0 010 $a0-323-54948-9 035 $a(CKB)4100000006096048 035 $a(MiAaPQ)EBC5508496 035 $a(EXLCZ)994100000006096048 100 $a20180927d2019 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aImmune checkpoint inhibitors in cancer /$fFumito Ito, Marc S. Ernstoff 210 1$aSt. Louis, Missouri :$cElsevier,$d[2019] 210 4$dİ2019 215 $a1 online resource (513 pages) 300 $aIncludes index. 327 $aImmune checkpoint inhibitors: mechanisms and emerging therapeutic opportunities -- Immune checkpoints: melanoma and other skin cancers -- The current status of immunotherapy in thoracic malignancies -- Immune checkpoint inhibitors in gastrointestinal malignancies -- Cancers of the head and neck -- Urologic malignancies -- Gynecologic malignancies -- Breast cancer -- Hematologic malignancies -- Pediatric malignancies -- Toxicities in immune checkpoint inhibitors -- Future of immune checkpoint inhibitors 606 $aCancer$xImmunological aspects 615 0$aCancer$xImmunological aspects. 676 $a616.994079 700 $aIto$b Fumito$0959146 702 $aErnstoff$b Marc S. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910583389903321 996 $aImmune checkpoint inhibitors in cancer$92173225 997 $aUNINA